2010
Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)
Abstract: Acta Ophthalmol. 2010: 88: 836–841 Abstract. Purpose: To perform a prospective study on central retinal vein occlusion (CRVO) to evaluate whether visual acuity can be improved and macular oedema reduced in response to intravitreal injections of bevacizumab. Methods: The case material comprised 13 patients (aged 34–79 years), duration of CRVO was 2 weeks to 6 months, baseline ETDRS visual acuity 0.06–0.4 (mean Snellen 0.13, derived from logMAR value) and intraocular pressure (IOP) 12–20 (mean 15.2) mmHg. Clin…
Search citation statements
Paper Sections
Select...
10
5
1
1
Citation Types
2
10
0
1
Year Published
Range
2008
2022
Publication Types
Select...
11
3
Relationship
1
13
Authors
Journals
Cited by 14 publications
(13 citation statements)
References 22 publications
2
10
0
1
Smart CitationsHow the paper below cites the one you are viewing
“…At baseline, BCVA was 42 ETDRS letters (0.13). After 1 IVB at baseline, average BCVA improved by 13 ETDRS letters at 6 weeks, and following 2 more IVB by 20 letters at 18 weeks, as previously reported (17). At 6 months and at 12 months, the mean increase of BCVA was 24 ETDRS letters (logMAR 0.48), from 0.13 (logMAR 0.86) at baseline to 0.4 (logMAR 0.38) (Fig.…”
Section: Results
supporting
confidence: 83%
Intravitreal Bevacizumab in Central Retinal Vein Occlusion: 18-month Results of a Prospective Clinical Trial
European Journal of Ophthalmology
Self Cite
Abstract